PAR-4 Agonist Peptide, CAS 352017-71-1

For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

US$514.80

Excluding tax and shipping fees

In stock

Description

About PAR-4 agonist peptide, CAS 352017-71-1

PAR-4 agonist peptide - (CAS 352017-71-1) is an agonist peptide for cancer research. The PAR-4 agonist peptide - (CAS 352017-71-1), H-AYPGKF-NH2 from JPT is produced under strict quality control and quality management.

PAR-4 agonist peptide - Specifications

Peptide sequence: H-AYPGKF-NH2

Amount: 5 mg

Purity: > 95% (HPLC/MS)

Counterion: TFA

Delivery Format: Freeze-dried in plastic vial

Application(s): Cancer research

Condition(s)/Topic(s): Cancer

Standard Delivery Time: approx. 3 weeks

Non-RGD Cancer Peptides from JPT

Cancer peptides are widely used to develop targeted diagnostic and therapeutic approaches. They offer different functionalities such as binding tumor-associated receptors, interacting with cellular membranes, or interfering with tumor microenvironment. Depending on the application, these mechanisms enable specific delivery, tumor imaging, and tumor cell killing with low side effects.JPT offers a wide portfolio of high-quality cancer peptides engineered for robust and reproducible research in oncology including RGD and non-RGD cancer peptides.

Benefits of JPT’s Non-RGD Cancer Peptides

Each peptide quality controlled and guaranteed for identity and purity

CoA and HPLC-MS data available

High batch-to-batch consistency

Synthesis protocols designed to avoid toxic contaminants and side products

Provision of freeze dried aliquots for enhanced stability

Proven track record for applications in clinical studies

References

References for PAR-4 agonist peptide, CAS 352017-71-1

ReferencesRead References with Peptides made by JPT

Testimonial:Our group focuses on the in vitro study of risk factors in Alzheimer’s disease and, as we experienced that the in-house expression and production of the amyloid beta peptide is notoriously difficult, we are continuously dependent on a high quality supply of a large variety of these peptides from commercial source.We started our collaboration with JPT with their request to test a range of their peptides for the ability to produce toxic oligomers and fibrillar networks and were impressed by the rapid supply of a very wide range of high purity peptides with excellent fibril forming properties and toxicity profiles. JPT has shown real valuable know-how and experience in the field of peptide synthesis by their ability to generate high quality preparations of amyloid beta peptide variants which are known for their difficulty to handle.Kerensa Broersen, Assistant Prof., Nanobiophysics Group, University of Twente, Enschede, The Netherlands

Documentation

Documentation for PAR-4 agonist peptide, CAS 352017-71-1

PAR-4-agonist-peptide-CAS-352017-71-1.pdf

Properties

Properties of PAR-4 agonist peptide, CAS 352017-71-1

5 mg

Cancer biomarker research

Cancer peptides, Cancer peptides Non-RGD

Cancer

Freeze-dried in plastic vial

>95% (HPLC-MS)

Further Information to PAR-4 agonist peptide, CAS 352017-71-1

Values

H-AYPGKF-NH2

PAR-4 Agonist Peptide, CAS 352017-71-1 | for Cancer Research